A Validated Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Aliskiren Hemifumarate and Amlodipine Besylate in Pharmaceutical Dosage Form

<table class="table-group" id="tab6"><tr><td><table class="table"><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr class="thead"><td align="left">Tablet</td><td align="center">Drug</td><td align="center">Dosage</td><td align="center">Amount found</td><td align="center">% assay</td></tr><tr><td class="thead-hr" colspan="5"><hr/></td></tr><tr><td align="left" rowspan="2">TAKEMLO</td><td align="center">Aliskiren</td><td align="center">150 mg</td><td align="center">148.72 mg</td><td align="center">99.15</td></tr><tr><td align="center">Amlodipine</td><td align="center">10 mg</td><td align="center">9.98 mg</td><td align="center">99.88</td></tr><tr class="table-tr"><td colspan="5"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Chromatography Research International

tab6

Table 6

Table 6: A Validated Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Aliskiren Hemifumarate and Amlodipine Besylate in Pharmaceutical Dosage Form 

Table 6 | A Validated Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Aliskiren Hemifumarate and Amlodipine Besylate in Pharmaceutical Dosage Form 